Mumbai: AstraZeneca Pharma India saw its shares go up by almost 12 per cent after the company reported strong Q4 results. The company’s profit for the quarter rose by 48 per cent year-on-year (Y-o-Y) to Rs 58.25 crore. This strong performance made investors happy, pushing the share price to Rs 8,919 during the day. This was the biggest one-day rise since March 20 this year. By mid-morning, the stock was trading 11.2 per cent higher at Rs 8,875, even though the Nifty50 index was down 0.54 per cent.
Sales and Profit Go Up
In the fourth quarter of FY25, AstraZeneca Pharma reported total revenue of Rs 480.48 crore. This was a 25.3 per cent increase compared to the same period last year. The company also posted strong growth across different therapy areas for the full year, with revenue rising 32 per cent compared to the previous year.
Growth in Key Areas
The oncology (cancer treatment) business was the biggest growth driver. In Q4 FY25, revenue from oncology rose to Rs 315.85 crore, a growth of 31.62 per cent from the year before. Revenue from biopharmaceuticals, including treatments for heart, kidney, respiratory, and immune-related diseases, rose 1.9 per cent to Rs 122.74 crore. The rare disease segment also grew, rising to Rs 2 crore in Q4 FY25, up from Rs 0.17 crore in Q4 FY24.
Management’s View
Bhavana Agrawal, the Chief Financial Officer and Director of AstraZeneca Pharma India, said, “FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent. This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.”
About the Company
AstraZeneca Pharma is part of the British-Swedish multinational AstraZeneca. It was formed in 1999 after the merger of Astra AB from Sweden and Zeneca Group from the UK. The company is known worldwide for making medicines for cancer, heart problems, infections, breathing issues, and more.
AstraZeneca Pharma has been in India for 45 years. It handles manufacturing, sales, and marketing in the country. It also gained global fame for its role in developing the Oxford–AstraZeneca Covid–19 vaccine.
